FEMASYS INC. - COMMON

Femasys Inc. Advances Commercial Readiness with Appointment of Richard Spector to New Position of Chief Commercial Officer

06 2 2024 08:30:00 提供 Nasdaq GlobeNewswire

Femasys Inc. Begins FemBloc Pivotal Trial Enrollment at UC Davis Medical Center, a Hub for Innovation and Groundbreaking Research in Health Care for Women

26 1 2024 08:00:00 提供 Nasdaq GlobeNewswire

Femasys Inc. Begins FemBloc Pivotal Trial Enrollment at University of Utah, an Internationally Recognized Center in Obstetrics and Gynecology

23 1 2024 08:30:00 提供 Nasdaq GlobeNewswire

Femasys Inc. Begins FemBloc Pivotal Trial Enrollment at Stanford Medicine

15 12 2023 08:30:00 提供 Nasdaq GlobeNewswire

Femasys Inc. Announces the Appointment of James Liu, M.D., as Chief Medical Officer

30 11 2023 08:30:00 提供 Nasdaq GlobeNewswire

Femasys Inc. Completes Enrollment of FemaSeed Pivotal Trial in Support of Commercial Launch

28 11 2023 08:30:00 提供 Nasdaq GlobeNewswire

Femasys Inc. Secures Additional Financing with Strategic Investment from Investors led by PharmaCyte Biotech

15 11 2023 07:30:00 提供 Nasdaq GlobeNewswire

Femasys Inc. Announces Financial Results for the Third Quarter Ended September 30, 2023 and Provides Corporate Update

14 11 2023 07:00:00 提供 Nasdaq GlobeNewswire

Femasys Inc. EU MDR Final Audit Successfully Completed

26 10 2023 08:30:00 提供 Nasdaq GlobeNewswire

Femasys Inc. to Showcase FemBloc and its other Novel Products Advancing Women’s Health at the American Association of Gynecologic Laparoscopic Surgeons

25 10 2023 08:00:00 提供 Nasdaq GlobeNewswire

Femasys Inc. Regains Compliance with Nasdaq Listing Requirements

11 10 2023 07:00:00 提供 Nasdaq GlobeNewswire

Femasys Inc. to Showcase FemaSeed at the Annual Meeting of the American Society of Reproductive Medicine

04 10 2023 08:30:00 提供 Nasdaq GlobeNewswire

Femasys Inc. MDSAP Surveillance Audit Successfully Completed

03 10 2023 08:30:00 提供 Nasdaq GlobeNewswire

Femasys Inc. Expands FemBloc Pivotal Trial Enrollment Securing First Academic Site to Participate

27 9 2023 08:00:00 提供 Nasdaq GlobeNewswire

Femasys Inc. Receives U.S. FDA Clearance to Market FemaSeed, an Innovative Infertility Treatment Solution

25 9 2023 17:25:04 提供 Nasdaq GlobeNewswire

Femasys Announces First-Patient-In for Pivotal Clinical Trial Evaluating its FemBloc Permanent Birth Control

20 9 2023 08:30:09 提供 Nasdaq GlobeNewswire

Femasys to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

06 9 2023 08:30:00 提供 Nasdaq GlobeNewswire

Femasys Inc. Obtains Medical Device Establishment License from Health Canada

31 8 2023 08:30:00 提供 Nasdaq GlobeNewswire

Femasys Inc. Announces Financial Results for the Second Quarter Ended June 30, 2023 and Provides Corporate Update

10 8 2023 08:00:01 提供 Nasdaq GlobeNewswire

Femasys Initiates Enrollment in Pivotal Trial of its Permanent Birth Control Candidate FemBloc

03 8 2023 08:45:00 提供 Nasdaq GlobeNewswire